Improved Detection of Fibrotic Nonalcoholic Fatty Liver Disease in Community-Based Referrals

被引:0
作者
Piao, Cindy [1 ,2 ]
Arteaga, Elvis J. [1 ]
Chen, Shuai [3 ]
Guo, Aili [1 ,4 ]
Macdonald, Scott T. [1 ,5 ]
Sarkar, Souvik [1 ,2 ,6 ]
机构
[1] Univ Calif Davis, Dept Internal Med, Davis, CA USA
[2] Univ Calif Davis, Div Gastroenterol & Hepatol, Davis, CA USA
[3] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA USA
[4] Univ Calif Davis, Div Endocrinol Diabet & Metab, Davis, CA USA
[5] Univ Calif Davis, Clin Informat, Davis, CA USA
[6] Intercoastal Med Grp, Gastroenterol & Hepatol, 3333 Cattlemen Rd, Sarasota, FL 34232 USA
关键词
NAFLD; NASH; diabetes; fibrosis; FIB-4; community; NAFLD;
D O I
10.1089/met.2023.0092
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease with increasing rates globally. Patients with type 2 diabetes mellitus have higher risk of developing NAFLD. Patients with a higher degree of liver fibrosis in NAFLD are at an increased risk for liver-related mortality, but get missed easily during the referral process. This project aims to improve early detection and linkage-to-care of fibrotic NAFLD patients. Methods: We utilized a combination of automated electronic health record (EHR)-based fibrosis (FIB)-4 score and directed provider education. A health-system wide FIB-4 score calculator that providers can easily add to their workflow for NAFLD patient triaging. Data were analyzed at 6 and 12 months after implementation. Results: Postimplementation, there was an increase in patients referred to hepatology with higher degree of liver fibrosis and decreased referral to hepatology with low risk of liver fibrosis, measured by FIB-4 score. At baseline, similar to 55% of referred patient to hepatology had FIB-4 score <1.3 compared to 38% at 12 months postimplementation. There was an increase in referral of patients with FIB-4 scores >1.3 when compared to preinterventions, 62% versus 45%. This is most pronounced in patients with severe fibrotic disease with FIB-4 score >2.67, 30% versus 12%. Conclusions: Automated FIB-4 score in EHR can improve appropriate linkage-to-care for at-risk fibrotic NAFLD, especially when coupled with targeted provider education. The durability of such improvement is essential to study along with the need to increase broad acceptance across health systems.
引用
收藏
页码:475 / 478
页数:4
相关论文
共 50 条
  • [41] Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
    Imajo, Kento
    Yoneda, Masato
    Kessoku, Takaomi
    Ogawa, Yuji
    Maeda, Shin
    Sumida, Yoshio
    Hyogo, Hideyuki
    Eguchi, Yuichiro
    Wada, Koichiro
    Nakajima, Atsushi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (11) : 21833 - 21857
  • [42] Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Kogachi, Shannon
    Noureddin, Mazen
    CLINICAL THERAPEUTICS, 2021, 43 (03) : 455 - 472
  • [43] Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)
    Gerhardt, Florian
    Petroff, David
    Blank, Valentin
    Boehlig, Albrecht
    van Boemmel, Florian
    Wittekind, Christian
    Berg, Thomas
    Karlas, Thomas
    Wiegand, Johannes
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 706 - 711
  • [44] Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review
    Roeb, Elke
    VISCERAL MEDICINE, 2022, 38 (02) : 126 - 132
  • [45] Nonalcoholic Fatty Liver Disease
    Wang, Xiao Jing
    Malhi, Harmeet
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (09) : ITC65 - ITC80
  • [46] Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Gawrieh, Samer
    Chalasani, Naga
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 189 - +
  • [47] Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes
    Mantovani, Alessandro
    Targher, Giovanni
    Zoppini, Giacomo
    CLINICS IN GERIATRIC MEDICINE, 2020, 36 (03) : 527 - +
  • [48] Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges
    Thiagarajan, Prarthana
    Aithal, Guruprasad P.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 9 (04) : 515 - 521
  • [49] Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease
    Miyaaki H.
    Nakao K.
    Clinical Journal of Gastroenterology, 2017, 10 (3) : 201 - 207
  • [50] Nonalcoholic fatty liver disease from a primary care perspective
    Clark, Jeanne M.
    Cryer, Donna R. H.
    Morton, Michelle
    Shubrook, Jay H.
    DIABETES OBESITY & METABOLISM, 2023, 25 (06) : 1421 - 1433